Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment …
Full DERM analysis →
Competitive advantage assessment
Key strengths
Strong Interest Coverage & Conservative LeverageDebt serviceability is strong (score 0.73), with robust interest coverage.
Operating Leverage in EffectOperating leverage is evident (score 0.66), with margins expanding over time.
Key risks
Weak or Negative Cash FlowCash generation is weak (score 0.31), limiting financial flexibility.
Where DERM ranks in Drug Manufacturers - Specialty & Generic
Journey Medical Corporation ranks #47 of 91
scored companies in Drug Manufacturers - Specialty & Generic by moat score — the top 52%.
The widest moat in the group is Zoetis Inc. (ZTS)
at 85/100.
Moat scores for companies ranked near DERM in Drug Manufacturers - Specialty & Generic
Pricing power is the ability to raise prices without losing volume.
Cost Advantage
Score 34
· 15% of the moat score
A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.
Customer Stickiness
Score 34
· 15% of the moat score
Stickiness is what makes revenue repeat without being re-won every year.
Capital Efficiency
Score 26
· 18% of the moat score
Capital efficiency asks what the company earns on the money tied up in the business.
Resilience
Score 54
· 17% of the moat score
Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.
Scale & Market Position
Score 59
· 15% of the moat score
Scale matters only when it converts into economics.
Journey Medical Corporation (DERM) scores 40 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #47 of 91 scored companies in Drug Manufacturers - Specialty & Generic, the top 52%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 90 companies in Drug Manufacturers - Specialty & Generic. Its strongest defense is Scale & Market Position (59/100) and its weakest is Capital Efficiency (26/100).
How does Journey Medical Corporation compare with other Drug Manufacturers - Specialty & Generic companies?
Journey Medical Corporation ranks #47 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score. The widest moat in Drug Manufacturers - Specialty & Generic is Zoetis Inc. (ZTS) at 85/100. The companies ranked closest are Aytu BioPharma, Inc. (AYTU) at 42 just above it and Lifecore Biomedical, Inc. (LFCR) at 40 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 90 companies in Drug Manufacturers - Specialty & Generic. The defenses are then weighted to produce the overall score out of 100.
Why is Journey Medical Corporation scored with the Corporate Default template?
Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.
Which competitive defenses are measured for Journey Medical Corporation?
The Corporate Default template measures 6 defenses, and DERM scores: Pricing Power (38), Cost Advantage (34), Customer Stickiness (34), Capital Efficiency (26), Resilience (54), Scale & Market Position (59). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.